Pure bull re. biotech. Fact is he picked lousy stocks. And, when he picked good ones, he bailed early, failing to see things clearly.
For example, he did pick AGPH early (although not without coaching, IMO). When the company decided to "go" with Viracept, he said that it was a mistake and recommended a sell at his split-adjusted target of $12 1/2.
I hate it when WSJ reports without balance. Yes, they pointed at the lousy performance, but they didn't point to the truth in response to his biotech excuses...... his picks have been amateurish.
Go back through the S.I. biotech threads for his disastrous picks. How many independent-thinking, scientist S.I. biofreaks were posting to those threads? Zero? Gee, wonder why.
I have nothing personal against the guy. However, as for von Emster of the Franklin Funds, I will track these guys and point at their bull when they finger the sector as a cause of their poor performance. The true cause????..... they don't belong in a leadership position for biotech funds. Pure and simple.
Stop dumping on the sector, guys. You're incompetent. Live with it. |
